Global Squamous Non-Small Cell Lung Cancer Market Pipeline Report 2021-2031: Mechanism of Action, Dosage and Administration, Pharmacological Studies, Regulatory Milestones
Wednesday, October 27, 2021
DUBLIN, Oct. 19, 2021 /PRNewswire/ -- The "Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The "Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report features an extensive study on the marketed, clinical and preclinical molecules available/being developed for the treatment of Squamous Non-Small Cell Lung Cancer.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies.
In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product's mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.
One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Squamous Non-Small Cell Lung Cancer, over the next decade.
Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2021-2031.
Scope of the Report
-- A detailed assessment of the therapeutic pipeline activity and
therapeutic assessment of the products by development stage, type of
therapy, route of administration, type of molecule, line of therapy,
dose strength and dose frequency across the complete product development
cycle, including all clinical and nonclinical stages.
-- Detailed drug profiles that are either approved or in late stages of
development for the treatment of squamous non-small cell lung cancer
have been presented, featuring overview of the company, overview of the
drug, clinical trial information, recent developments (such as clinical
trial results, collaborations and conferences) and estimated sales
revenue.
-- A detailed analysis identifying the key opinion leaders (KOLs),
featuring a 2X2 analysis to assess the relative experience of certain
KOLs who were shortlisted based on their contributions (in terms of
involvement in various clinical studies) to this field.
-- An analysis of the partnerships that have been established in the
domain, over the last five years, covering research agreements,
product/technology licensing agreements, mergers/acquisitions, asset
purchase agreements, R&D and commercialization agreements, IP licensing
agreements, clinical trial agreements, product development agreements,
and other relevant deals.
-- A detailed analysis of completed, ongoing and planned clinical studies,
based on the various relevant parameters, such as trial registration
year, trial phase, number of patients enrolled, study design, trial
recruitment status, and trial focus, highlighting leading sponsors, type
of organization, and regional distribution of trials. In addition, it
features an insightful clinical end-points analysis.
Key Questions Answered
-- What are the prevalent R&D trends related to squamous non-small cell
lung cancer?
-- What are the key challenges faced by stakeholders engaged in this
domain?
-- What are the principal therapies developed by the companies in this
domain?
-- Who are the leading industry and non-industry players in this market?
-- What are the contributions of big pharma players in this field?
-- What are the key geographies where research on squamous non-small cell
lung cancer is being conducted?
-- Who are the key investors in this domain?
-- Who are the key opinion leaders/experts in this field?
-- What kind of partnership models are commonly adopted by industry
stakeholders?
-- What are the factors that are likely to influence the evolution of this
upcoming market?
-- How is the current and future market opportunity likely to be
distributed across key market segments?
Key Topics Covered:
1. BACKGROUND
2. EXECUTIVE SUMMARY
3. CURRENT MARKET LANDSCAPE
3.1. Market Landscape of Squamous NSCLC Drugs
3.2. Market Landscape of Squamous NSCLC Drug Developers
4. PRODUCT PORTFOLIO COMPETITIVENESS
4.1. Analysis by Geography
5. KEY MARKET INSIGHTS
5.1. Clinical Trial Analysis
5.2. Partnerships and Collaborations
5.3. KOL Analysis
6. MARKET FORECAST
6.1. Market Share by Type of Molecule / Drug Class
6.2. Market Share by Type of Therapy
6.3. Market Share by Route of Administration
6.4. Market Share by Geography
7. DRUG PROFILES
7.1. Afatinib
7.2. Pembrolizumab
7.3. Cadi 05
7.4. Nivolumab
7.5. Necitumumab
7.6. Tislelizumab
7.7. Camrelizumab
7.8. Canakinumab
7.9. Serplulimab
7.10. Ipilimumab
7.11. KN046
7.12. Cemiplimab
7.13. Niraparib
7.14. Penpulimab
7.15. Retifanlimab
7.16. SCT-I10A
7.17. Sintilimab
7.18. Atezolizumab
7.19. Toripalimab
7.20. Zimberelimab
7.21. AZD4547
7.22. Palbociclib
8. APPENDIX 1: TABULATED DATA
9. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/rj60vw
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-squamous-non-small-cell-lung-cancer-market-pipeline-report-2021-2031-mechanism-of-action-dosage-and-administration-pharmacological-studies-regulatory-milestones-301403095.html
SOURCE Research and Markets
|
|
|
|
|
 |
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
|
